SCHEMBL2809627

SCHEMBL2809627

c1cnc2ncc3ncsc3c2c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
KDM4E B2RXH2 3/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HSP90AA1 P07900 2/20 0.34
MEN1 O00255 1/20 0.34
HSP90AB1 P08238 1/20 0.34
HTT P42858 1/20 0.34
BLM P54132 1/20 0.34
KMT2A Q03164 1/20 0.34
HIF1A Q16665 1/20 0.34
MAOB P27338 1/20 0.32
CYP3A4 P08684 1/20 0.32
NPC1 O15118 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
RIPK1 Q13546 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30402017 0.76 ALDH1A1 (0.47) KDM4EALDH1A1HSD17B10
SCHEMBL3943646 0.76 MAPT (0.58) LMNAKDM4EMAPTALDH1A1HSD17B10
SCHEMBL2401192 0.76 ALDH1A1 (0.47) KDM4EALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL10466114 0.74 ALDH1A1 (0.45) KDM4EALDH1A1HSD17B10NPC1
Ammonia Solution, Strong SCHEMBL6783413 0.74 ALDH1A1 (0.45) KDM4EALDH1A1HSD17B10NPC1
SCHEMBL2809624 0.73 KDM4E (0.45) LMNAKDM4EMAPTALDH1A1HSD17B10
SCHEMBL2290363 0.72 MAPT (0.58) LMNAKDM4EMAPTALDH1A1HSP90AA1
SCHEMBL8599122 0.71 LMNA (0.57) LMNAKDM4EMAPTHSP90AA1MEN1
SCHEMBL13629318 0.67 KDM4E (0.45) LMNAKDM4EMAPTALDH1A1HSP90AA1
SCHEMBL13166536 0.67 MAPT (0.50) LMNAKDM4EMAPTHSP90AA1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378102-B2 Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-02-19 US disclosed
US-20100240693-A1 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC (US) 2010-09-23 US disclosed
EP-1877056-A2 OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLOÝ4,5-C¨RING COMPOUNDS AND METHODS Coley Pharmaceutical Group, Inc. (US) 2008-01-16 EP disclosed
WO-2007120121-A2 OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLO[4,5-C] RING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240693-A1 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods IL4, IL2, TH LMNA 4623/4885KDM4E 1175/4885MAPT 3605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.